VistaGen Therapeutics Inc. (NASDAQ:VTGN) currently has a daily average trading volume of 6.80M but it saw 2104722 shares traded on Wednesday. With a market cap of 35.76M USD, stock’s current market price of $0.15 came rising about 4.74 while comparing to the previous closing price of $0.15. In past 52 weeks, the stock remained buoying in the range of price level as high as $1.79 and as low as $0.08. In the recent trading on the day, stock has struck highest price mark of $0.1559 while lowest mark touched by it was $0.1433.
From Robots to Self-Driving Cars: 5 AI Stocks to Consider for Your Portfolio
The artificial intelligence (AI) revolution is already here and it's about to change everything we know about everything. With the global market for AI projected to grow from $137 billion in 2022 to over $1.81 trillion by 2030, there's never been a better time to invest in this burgeoning industry. That's why we've compiled a list of the Top 5 AI Stocks to Buy for 2023. These companies are at the forefront of the AI revolution, and have the potential to deliver huge returns to investors like you.
Get our free report, "Top 5 AI Stocks to Buy for 2023".
Sponsored
Taking a look at 20-day trading activity of VistaGen Therapeutics Inc. (VTGN) gives us an average price of $0.1692, while its current price level is -91.47% below from 52-week high level whereas it is 98.70% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $0.1833 while that of 200 days or SMA-200 reads an average of $0.3080. A closer look into the stock’s movement over the week reveals that its volatility is standing at 12.35% during that period while stretching the period over a month that decreases to 11.04%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 44.06 which implies that the stock is in neutral territory.
VistaGen Therapeutics Inc. (VTGN)’s stock is currently under the radar of 2 analysts who are in consensus at a 12-month price target range of between $0.25 and $0.25 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $0.25 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $0.25. Average price target assigned by them is $0.25 which highlights an upside potential of 40.0% for the stock over that period. And to attain the median price target of $0.25 assigned by those analysts, stock has to add about 40.0% of value to its current levels.
Data by FactSet Research shows that 2 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 0 analysts suggested the investors to Buy the stock while 2 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Hold for the stock and that issued by Wall Street to investors is Hold.
Over the week, VTGN’s stock price is moving 1.67% up while it is -33.33% when we observe its performance for the past one month. Year-to-date it is 48.16% up and over the past year, the stock is showing a downside performance of -86.61%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2022, when its quarterly earnings per share (EPS) of -$0.05 beat the consensus estimate of -$0.07 for the same. The company is expected to be releasing its next quarterly report in 06/27/2023, for which analysts forecasted an EPS of -$0.06 while estimate for next year EPS is -$0.3. For VTGN, analysts are forecasting an EPS-growth rate of -20.00% for current year and estimate for EPS growth in next year is 16.70%. In next quarter, company is expected to be making quarterly sales of $180k as analysts are expecting the sales for current fiscal year at $40k and seeing the company making $370k in sales next year. Moreover, analysts are in estimates of $90k for current-quarter revenue.
Currently, VistaGen Therapeutics Inc.’s total number of outstanding shares is 206.84M with 0.84% of that held by the insiders while 22.21% of its common stock has been owned by the institutions. Company’s return on investment (ROI) stands at -73.90% and return on equity (ROE) at -158.20%. Stock’s beta reads 1.07. Stock has a price to book (P/B) ratio of 1.53. Its return on asset (ROA) is -125.10% on average.
A filing at the U.S. Securities and Exchange Commission revealed that iShares Russell 2000 ETF came shrinking its share ownership by -0.32% in the VistaGen Therapeutics Inc. (VTGN) decreasing its stake to 1.98% with control over 13752.0 shares in the company.
